Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

108.86 +0.72 (+0.67%)

Streaming Delayed Price Updated: 1:12 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9

...

48 49 Next >

The Best Dividend Stocks to Buy and Hold Forever ↗

March 12, 2026

They are relatively safe wealth compounders.

Via The Motley Fool

Topics Intellectual Property

Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks

March 11, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...

Via StockStory

Macroeconomic Headwinds and Shifting Demand Force Healthcare Giants to Trim 2026 Outlooks

March 09, 2026

As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Abbott Laboratories (NYSE:ABT) Emerges as a Top Dividend Stock with Strong Fundamentals ↗

March 02, 2026

Via Chartmill

2 Profitable Stocks on Our Watchlist and 1 We Avoid

March 09, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"

March 04, 2026

As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

2 Reasons to Like ABT and 1 to Stay Skeptical

March 01, 2026

Over the last six months, Abbott Laboratories’s shares have sunk to $116.31, producing a disappointing 11.5% loss - a stark contrast to the S&P 500’s 7.7% gain. This was partly driven by its softer...

Via StockStory

Topics Stocks Supply Chain

Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time ↗

February 25, 2026

Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend.

Via The Motley Fool

Topics Cannabis Initial Public Offering

The Great Unlocking: Medtronic’s Strategic Pivot and the MiniMed Spin-Off

February 24, 2026

Date: February 24, 2026 By: Financial Research Analyst Introduction For years, Medtronic plc (NYSE: MDT) was viewed by Wall Street as a reliable but sluggish giant—a "Dividend Aristocrat" that offered...

Via Finterra

Topics Artificial Intelligence Economy Initial Public Offering

Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich ↗

February 23, 2026

"Boring" may be just what the doctor ordered in this volatile market.

Via The Motley Fool

Topics Artificial Intelligence

Medtronic Hits 10-Quarter High: PFA Dominance and Robotic Surges Signal a New Era for MedTech

February 23, 2026

In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape

February 19, 2026

On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire...

Via MarketMinute

Medtronic Hits Ten-Quarter Growth Peak in Q3 Fiscal 2026, Signaling Resurgence in MedTech Sector

February 19, 2026

Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for its fiscal third quarter of 2026, marking a significant turning point for the medical technology giant. The...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

3 Large-Cap Stocks with Solid Fundamentals

February 18, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues

February 18, 2026

Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings...

Via MarketMinute

Topics Earnings

Medtronic (MDT): The Sleeping Giant Awakes with Strong Q3 FY26 Momentum

February 17, 2026

Today’s Date: February 17, 2026 Introduction Medtronic plc (NYSE: MDT) has long been the sleeping giant of the medical technology sector. For years, the Dublin-domiciled powerhouse was viewed by Wall...

Via Finterra

Topics Artificial Intelligence Earnings Economy

2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 We Turn Down

February 15, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky

February 12, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever ↗

February 12, 2026

Abbott is the name behind many well-known products.

Via The Motley Fool

1 Reason I'm Never Selling AbbVie Stock ↗

February 12, 2026

This Dividend King has staying power.

Via The Motley Fool

Topics Intellectual Property

Pure-Play Pivot: Decoding Becton Dickinson’s (BDX) Q1 Results and the $17.5B Waters Combination

February 09, 2026

Today, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5...

Via Finterra

Topics Artificial Intelligence Economy Product Recall

The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map

February 06, 2026

As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A...

Via MarketMinute

Topics Artificial Intelligence Economy

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal ↗

February 05, 2026

Via MarketBeat

Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)

February 05, 2026

February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left...

Via Finterra

Topics Product Recall World Trade

2 Healthcare Dividend Stocks That are Just What the Doctor Ordered ↗

February 03, 2026

AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.

Via The Motley Fool

Topics Intellectual Property

The Best Dividend King to Buy With $150 ↗

February 02, 2026

The stock is near its 52-week low.

Via The Motley Fool

Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race

February 02, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The...

Via MarketMinute

Topics Artificial Intelligence

Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist ↗

January 31, 2026

These market giants make great long-term investments.

Via The Motley Fool

5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call

January 29, 2026

Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this...

Via StockStory

Topics Earnings

3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗

January 26, 2026

Investors' reaction to this Dividend King's Q4 revenue miss was overdone.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

48 49 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.